ClinicalTrials.gg
RecruitingNCT07118722Updated Aug 25, 2026

Mindfulness-based Cognitive Therapy vs the Health Enhancement Program for Chronic Pain and Depression; The Quiet Focus Study

An interventional study of Quiet Focus and Health Enhancement Program in Chronic Pain and Depression, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 50 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Chronic Pain by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Chronic Pain · Massachusetts General Hospital.

Planned enrollment
11th of 23
60 · median 60
Started
2025
with 2 others
No phase
20 of 27
5 open now
Registered
23rd of 27
by date

Among the 27 studies in Chronic Pain by Massachusetts General Hospital, this one is the 11th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 20 with no phase, and was the 23rd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

7 of the 27 studies in Chronic Pain by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 50 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Chronic Pain by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to pilot a randomized controlled trial comparing an adaptation of mindfulness-based cognitive therapy to the health enhancement program for chronic pain and depression. The main questions it aims to answer in a later fully powered randomized controlled trial are:

  • Is an adaptation of mindfulness-based cognitive therapy for older Black adults able to improve quality of life?
  • Will an adapted mindfulness based cognitive therapy reduce pain interference to a greater degree than a traditional health enhancement program?
Read the detailed description

Co-morbid chronic pain-depression is common among older Black adults and this co-morbidity worsens physical and emotional function. Access to evidence based non-pharmacological management is limited. Mindfulness based cognitive therapy (MBCT) is an evidence-based, non-pharmacological intervention that could address the chronic pain-depression co-morbidity among older Black adults, but it requires tailoring. The proposed study will establish the feasibility, acceptability and credibility of Quiet Focus, a cultural adaptation of MBCT aimed at the chronic pain-depression co-morbidity among older Black adults in the community.

03

Conditions studied

  • Chronic Pain
  • Depression

Keywords

  • mindfulness-based cognitive therapy
  • mind-body
  • chronic pain
  • depression
  • older adult
04

Who can participate

Ages eligible
50 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participant Inclusion Criteria

  1. Older adult (age ≥ 50)
  2. All individuals who identify with one or more nationalities or ethnic groups originating in any of the Black racial groups of Africa
  3. Pain in muscles, joints, bones, or associated soft tissues (NRS>4) lasting longer than 3 months
  4. Depressed (PHQ-9 score of 5-14)
  5. English fluency/literacy
  6. Ability and willingness to participate via in-person and video
  7. No change to type or dose of antidepressant medications for at least 6 weeks prior to screening
  8. Willing to provide and comply with all aspects of the protocol

Participant Exclusion Criteria

  1. Moderately severe or severe depressive symptoms (PHQ-9 ≥ 15)
  2. Current substance abuse/dependence
  3. Significant cognitive impairment
  4. History of more than 8 sessions of cognitive-behavioral therapy
  5. History of previous training in mindfulness or undergoing counseling more than once a month
  6. History of or current diagnosis of psychosis
  7. Active suicidal ideation (PHQ-9 item #9 or otherwise reported during screening) or self-harm within the past 90 days
  8. Current participation in another behavioral clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Quiet Focus

    Behavioral: Quiet Focus

  • Active comparator
    Health Enhancement Program

    Behavioral: Health Enhancement Program

Interventions

  • BehavioralQuiet Focus

    Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression

  • BehavioralHealth Enhancement Program

    Time- and dose-matched control for Quiet Focus.

06

What researchers measure

Primary outcomes

  1. The Credibility and Expectancy Questionnaire

    This scale measures participant expectations around the study's positive outcomes, with measures ranging from 0 (not at all expected) to 9 (extremely expected). A higher score indicate greater trust in the study design and an openness to potential benefits.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  2. The Client Satisfaction Questionnaire

    Three item scale measuring patient satisfaction with the program. Scores for each item range from 1 (unsatisfied) to 4 (very satisfied).

    Time frame: Administered at the end of treatment at 8 weeks and at the three month follow up visit

  3. Modified Patient Global Impression of Change

    Measures participant impressions of overall change with one being very much improved and eight being very much worse. Lower scores indicate improvement.

    Time frame: At end of 8 week program (post test) and again at 3 month follow up visit

Secondary outcomes

  1. Numerical Rating Scale

    Numerical rating of pain with lower scores indicating less pain overall (0 = no pain) and higher scores indicating more pain (10 = worst ever pain) over the past week.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  2. PROMIS Physical Function

    The PROMIS Physical Function raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Unable to do" and 5 = "Without any difficulty," with higher scores indicating better function. This raw score is then converted to a T-score using a standardized table, where 50 represents the average in the general population and 10 is the standard deviation.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  3. PROMIS Depression

    The PROMIS Depression raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Never" and 5 = "Always," with higher scores indicating more severe depressive symptoms. This raw score is converted to a T-score using a standardized table, where 50 represents the average level in the general population and 10 is the standard deviation.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  4. PROMIS Anxiety

    The PROMIS Anxiety raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Never" and 5 = "Always," with higher scores reflecting greater anxiety symptoms. The raw score is then converted to a T-score using a standardized scoring table, with 50 representing the population average and 10 as the standard deviation.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  5. PROMIS Emotional Support

    The PROMIS Emotional Support raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Never" and 5 = "Always," with higher scores indicating greater perceived emotional support. This raw score is converted to a T-score using a standardized table, where 50 represents the average for the general population and 10 is the standard deviation.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  6. Measure of Current Status Part A

    The Measure of Current Status Part A (MOCS-A) is a self-report questionnaire that measures ability to manage stress. The score is calculated by summing responses to each item, rated on a 5-point Likert scale where 0 = "I cannot do this at all" and 4 = "I can do this extremely well," with higher scores reflecting greater confidence in coping skills. The scale measures current perceived ability to manage stress across areas like relaxation, awareness of tension, assertiveness, and coping confidence.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  7. Cognitive and Affective Mindfulness Scale-Revised

    The Cognitive and Affective Mindfulness Scale - Revised (CAMS-R) measures percieved ability to complete mindfulness tasks such as meditation, with a 0 being rarely/not at all and a 3 being almost always. Higher scores indicate greater ability to practice mindfulness skills.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  8. Chronic Pain Acceptance Questionnaire

    The Chronic Pain Acceptance Questionnaire (CPAQ)\*= raw score is calculated by summing responses to each item, rated on a 7-point Likert scale where 0 = "Never true" and 6 = "Always true," with higher scores indicating greater acceptance of chronic pain. The scale assesses two key areas: pain willingness(the ability to experience pain without trying to control or avoid it) and activity engagement (continuing meaningful activities despite pain).

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  9. Pain Self-Efficacy Questionnaire

    The Pain Self-Efficacy Questionnaire (PSEQ) measures confidence in engaging in activities despite chronic pain. Higher scores indicate greater confidence (6 = complete confidence) and lower scores indicate lower confidence (0 = not at all confident).

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  10. Pain Catastrophizing Scale

    The Pain Catastrophizing Scale (PCS) score is calculated by summing responses to each item, rated on a 5-point Likert scale where 0 = "Not at all" and 4 = "All the time," with higher scores indicating greater levels of catastrophic thinking related to pain. The scale measures three components of pain catastrophizing: rumination, magnification, and helplessness.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

  11. Tampa Kinesiophobia Scale

    The Tampa Kinesiophobia Scale (TKS) measures fear of movement and is calculated by summing responses to each item, rated on a 4-point Likert scale where 1 = "Strongly disagree" and 4 = "Strongly agree," with higher scores indicating greater fear of movement or reinjury due to physical activity.

    Time frame: From enrollment to 3 months from the end of treatment at 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 16 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 12, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07118722
Responsible party
Tony V. Pham, MD (Principal Investigator and Psychiatrist, Massachusetts General Hospital) — Principal investigator
First posted
Aug 12, 2025
Start date
Sep 1, 2025
Primary completion
Jan 15, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Tony V Pham
Contact
tonyvpham@mgh.harvard.edu
617-800-9988
Tony V Pham
Contact
Tony V Pham
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion